Enabling Noninvasive Systemic Delivery

Dr. Michael W. Pennington, President and CEO of Peptides International, is the coauthor of another in the latest series of publications devoted to potassium channel blockers.  In the linked article, published in the Journal of Pharmaceutical Sciences, he and his coauthors look at alternatives to delivery of the peptide HsTX1[R14A], which is a potent and selective blocker of the voltage-gated potassium channel Kv1.3.  Kv1.3 is a well-recognized therapeutic target for autoimmune diseases.  Unfortunately, with poor oral absorption and to avoid the need for constant and regular injections, an alternative is required.  Therefore, the potential of the buccal mucosa for systemic delivery of HsTX1[R14A] was investigated by in vitro studies, and exhibited promising potential as an alternative delivery method.  The article (may require subscription) is available through this link: http://www.jpharmsci.org/article/S0022-3549(16)41442-5/abstract

Peptides International News

Robert Brousseau

See all articles from Robert Brousseau

Robert Brousseau, the Director of Marketing and Catalog Sales Development at Peptides International, has a wide range of responsibilities that include maintaining the Peptides International brand integrity and creating and implementing all materials related to marketing the company's product line. He is also tasked with the catalog portfolio sales.  Since joining the company in 2004, he has incorporated media that now includes printed material such as product brochures and the long-running PEPNET newsletter, along with the company Website, social media, email and other outlets.  Additionally, he assists the staff with IT issues they encounter.  Bob has a background in graphic design, marketing, and advertising, in addition to project management and packaging.  He received his B.A. in Art from the University of Louisville, with additional post-graduate studies in education and design.